Crucell

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Crucell N.V.
Type Privately held naamloze vennootschap; subsidiary
Industry Biotechnology
Founded 2000
Headquarters Leiden, Netherlands
Key people Ronald Brus (CEO), Jan Pieter Oosterveld (Chairman of the supervisory board)
Products Vaccines and antibodies
Revenue 329.8 million (2010)[1]
Operating income Decrease (€34.3 million) (2010)[1]
Profit Decrease (€27.6 million) (2010)[1]
Total assets €967.1 million (end 2010)[1]
Total equity €786.4 million (end 2010)[1]
Owner(s) Johnson & Johnson
Employees 1,250 (2009)[2]
Website www.crucell.com

Crucell is a biotechnology company specializing in vaccines and antibodies. The firm, a subsidiary of Johnson & Johnson, is headquartered in Leiden, Netherlands. Crucell shares were previously listed on the Euronext Amsterdam exchange and formed part of the AMX index until April 2011, when J&J completed a tender offer for the company.

History[edit]

In 1993 Introgene, Crucell’s predecessor, was established as a spin-off of Leiden University. The company formed a partnership with Genzyme to collaborate on its vector technology and viral-based products. In 1999 the company founded Galapagos Genomics as a joint venture together with Tibotec. In 2000 IntroGene acquired U-Bisys to form Crucell.

In 2006, Crucell and Swiss Berna Biotech; Swedish SBL Vaccines and US-based Berna Products joined forces to become the sixth largest vaccine company worldwide, with their own clinical programs.

On 7 January 2009 Crucell released a press release saying Crucell and Wyeth were in discussion on a merger of the two companies. On 26 January 2009 Crucell released another press release saying the discussions on a combination of Crucell and Wyeth was discontinued due to Pfizer's acquisition of Wyeth.

On 28 September 2009 Johnson & Johnson bought 18% stake in Crucell for €302 million in order to collaborate on the development of a flu vaccine.[3] This follows in the wake of Crucell's discovery of CR6261, a potent human antibody that neutralizes a broad range of influenza A viruses. J&J agreed to acquire the rest of the company in October 2010, taking its stake to over 95% by February 2011[4] and delisting the company from stock exchanges two months later.[5]

Vaccine products[edit]

Paediatric[edit]

  • Quinvaxem
  • Hepavax-Gene
  • MoRu-Viraten
  • Epaxal-Junior

Travel and endemic[edit]

Respiratory[edit]

  • Inflexal V

Quinvaxem Vaccine controversy[edit]

Vietnamese reports[edit]

It was reported that since the Quinvaxem vaccine was first used in 2007, at least 63 children have died after being vaccinated in Vietnam. After the initial report of child deaths post Quinvaxem vaccination, the vaccine was suspended by the Vietnamese Health Ministry in May 2013 after children died post-vaccination.[6] The vaccine was subsequently banned in Vietnam and created a stir amongst parents about to give the vaccination to their their infantile children. [7]The Ban was later lifted following an investigation initiated by WHO and UNICEF.

UNO & UNICEF approval and the Quinvaxem vaccine[edit]

The World Health Organization (WHO) and UNICEF jointly confirmed in December of 2013 that the 5 in 1 or pentavalent Quinvaxem vaccine, suspected of playing a role in 63 children’s deaths post-vaccination, was safe to use. [8]In an independent inquiry and based on their investigation and post-mortem reports they declared that no connection could be found between the use of the vaccine and the Vietnamese children's deaths. The investigation found the vaccine to be safe for vaccination and failed to establish a link between the vaccine and the reported deaths and stated that they were "coincidental health problems related in time but not related to the use of Quinvaxem". WHO additionally stated the Quinvaxem vaccine has been distributed to 90 countries and administered approximately 400 million times since 2006 with no fatalities associated with the vaccine. [9]

The Quinvaxem vaccine had been used again since October 2013 after investigations by the health authorities showed that there were no unsafe cases in relation to the use of this vaccine. [10]

References[edit]

  1. ^ a b c d e "Annual Results 2010". Crucell. Retrieved 27 February 2011. 
  2. ^ "Annual Report 2009". Crucell. Retrieved 2010-05-23. 
  3. ^ Gray-Block, Aaron (28 September 2009). "Johnson & Johnson buys 18 pct stake in Crucell". Reuters. Retrieved 28 September 2009. 
  4. ^ Solsman, Joan E. (17 February 2011). "J&J: Sufficient Number Of Crucell Holders Tender Shares". The Wall Street Journal. Dow Jones Newswires. Retrieved 27 February 2011. 
  5. ^ Gray-Block, Aaron (11 April 2011). "Crucell to be delisted after J&J buyout". Reuters. Retrieved 16 April 2011. 
  6. ^ "Another baby dies after Quinvaxem vaccination". Tuoitrenews. 16 January 2014. Retrieved 16 January 2014. 
  7. ^ "One more vaccine-related death triggers worries in Vietnam". China Central Television. 21 March 2014. Retrieved 21 March 2014. 
  8. ^ "WHO, UNICEF confirm safety of Quinvaxem vaccine". Tuoitrenews. 20 December 2013. Retrieved 20 December 2013. 
  9. ^ "Safety of Quinvaxem (DTwP-HepB-Hib) pentavalent vaccine.". World Health Organisation (WHO). WHO. Retrieved 10 May 2013. 
  10. ^ "Update on quality and safety of Quinvaxem (DTwP-HepB-Hib) pentavalent vaccine.". World Health Organization. 5 July 2013. Retrieved 5 July 2013. 

External links[edit]